Firebrick Pharma
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 1 July 2026
- Reported shorts
- 19.2K
- Shares on issue
- 285.199M
Firebrick Pharma (FRE) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $106.0KM (source: ASX (Markit))vs $293.4K (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$3.1MM (source: ASX (Markit))vs −$2.6M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.012T (source: Derived: trailing 12 months at year end)vs −$0.013 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −63.9%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E and Annual Report 30 June 2026, 31 Aug 2026
Firebrick Pharma's annual revenue fell 64% to $106,000 for the year ended 30 June 2026, while its net loss widened 16% to $3.1 million. No dividends were declared. The company notes it has graduated to early commercialisation with approvals and launches in several markets, but its auditor has highlighted a material uncertainty about its ability to continue as a going concern.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −2,889.1%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $106.0KM (source: ASX (Markit)) | $293.4K | $14.5K | $830 |
| Gross profit | n/a | $104.8K | −$22.8K | $830 |
| Operating income | n/a | −$2.9M | −$3.9M | −$6.9M |
| EBITDA | n/a | −$2.9M | −$1.2M | −$6.9M |
| EBIT | n/a | −$2.9M | −$1.2M | −$6.9M |
| Interest expense | n/a | n/a | $1.0K | n/a |
| Pretax income | n/a | −$2.6M | −$1.2M | −$6.8M |
| Tax | n/a | $0 | $0 | $0 |
| NPAT | −$3.1MM (source: ASX (Markit)) | −$2.6M | −$1.2M | −$6.8M |
| Net interest income | n/a | $9.2K | $16.0K | $39.9K |
| EPS basic | −$0.012T (source: Derived: trailing 12 months at year end) | −$0.013 | −$0.007 | −$0.040 |
| EPS diluted | −$0.012T (source: Derived: trailing 12 months at year end) | −$0.013 | −$0.007 | −$0.040 |
| Shares | n/a | 224.6M | 195.3M | 176.2M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual Report 30 June 2026Annual Results31 Aug 2026via asx_announcements
- March 2026 Quarterly Activity Report & Appendix 4CQuarterly Report21 Apr 2026via asx_announcements
- Appendix 4D & Half-Year Financial Report to 31 December 2025Half Year Results24 Feb 2026via asx_announcements
- December 2025 Quarterly Activity Report & Appendix 4CQuarterly Report28 Jan 2026via asx_announcements
- Annual General Meeting PresentationFinancial Report31 Dec 2025via crawler
- Firebrick Pharma Investor Update on Key ProjectsFinancial Report31 Dec 2025via crawler
- Firebrick Investor UpdateFinancial Report31 Dec 2025via crawler
- Investor Presentation – Euroz Hartleys Healthcare ForumInvestor Presentation31 Dec 2025via crawler
- Firebrick Presents at Euroz Hartleys Healthcare ConferenceFinancial Report31 Dec 2025via crawler
- Investor Presentation – Euroz Hartleys Rottnest ConferenceInvestor Presentation31 Dec 2025via crawler
Showing 10 of 27 reports